Haemonetics Q3 2025: Unpacking Contradictions in Plasma Growth, VASCADE Performance, and CSL Impact
Earnings DecryptThursday, Feb 6, 2025 12:34 pm ET

These are the key contradictions discussed in Haemonetics Corporation's latest 2025 Q3 earnings call, specifically including: Plasma Collection Growth Expectations, VASCADE Product Performance, and CSL Contribution:
Revenue Growth and Earnings Expansion:
- Haemonetics Corporation reported third-quarter revenue of $349 million, showing a 4% increase on a reported basis but flat organically.
- Earnings per share were up 14% to $1.19. This growth was attributed to strong performance in the hospital segment and a focus on higher-margin opportunities.
Plasma Segment Dynamics:
- Plasma revenue declined 9% in the third quarter, primarily due to the planned CSL divestiture and a 5% decline year-to-date.
- The decline was also driven by a temporary pullback in plasma collections and ongoing market disruptions, but the company expects to recover to historical growth rates with new technology and customer adoption strategies.
Hospital Segment Leadership:
- The hospital segment experienced 24% revenue growth on a reported basis, with organic growth of 12% in the third quarter.
- Growth was driven by strong performance in Blood Management Technologies, Hemostasis management, transfusion management, and Interventional Technologies, particularly in electrophysiology procedures.
Plasma Collection Technology Innovation:
- Haemonetics made progress in transitioning customers to its NexSys and Persona technologies, expecting these upgrades to substantially complete by the end of the fiscal year.
- The company's innovation, enabling cost reduction and improved donor safety, is enhancing market share and margin expansion in the plasma collections business.
Revenue Growth and Earnings Expansion:
- Haemonetics Corporation reported third-quarter revenue of $349 million, showing a 4% increase on a reported basis but flat organically.
- Earnings per share were up 14% to $1.19. This growth was attributed to strong performance in the hospital segment and a focus on higher-margin opportunities.
Plasma Segment Dynamics:
- Plasma revenue declined 9% in the third quarter, primarily due to the planned CSL divestiture and a 5% decline year-to-date.
- The decline was also driven by a temporary pullback in plasma collections and ongoing market disruptions, but the company expects to recover to historical growth rates with new technology and customer adoption strategies.
Hospital Segment Leadership:
- The hospital segment experienced 24% revenue growth on a reported basis, with organic growth of 12% in the third quarter.
- Growth was driven by strong performance in Blood Management Technologies, Hemostasis management, transfusion management, and Interventional Technologies, particularly in electrophysiology procedures.
Plasma Collection Technology Innovation:
- Haemonetics made progress in transitioning customers to its NexSys and Persona technologies, expecting these upgrades to substantially complete by the end of the fiscal year.
- The company's innovation, enabling cost reduction and improved donor safety, is enhancing market share and margin expansion in the plasma collections business.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet